Company intelligence
Biointron
Recombinant Antibody Expression, Delivery in 2 weeks (From Gene Sequence to Purified Antibody)
About Biointron
About Biointron: Founded in 2012 Certified to ISO 9001:2015 High-technology Enterprises CRO supplier for antibody discovery and expression Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization for global biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide. We provide antibody discovery, expression and optimization services, including VHH antibody discovery, single B-cell antibody screening, hybridoma sequencing, antibody humanization, antibody affinity maturation, and RushData (an AI antibody wet lab validation service that provides high-throughput wet lab validation for AI/ML-designed antibody candidates, turning computational predictions into experimentally confirmed data). Additionally, Biointron holds global sublicensing rights for ECACC's CHO-K1. Our CHOK1BN cell line, which is derived from CHO-K1, has been filed in the DMF system with the US FDA. By choosing the CHOK1BN cell line, several partners' projects have entered multicenter international clinical trials successfully. For more information, please visit our official website at www.biointron.com or contact us at info@biointron.com
Verified activity
Signals from Biointron
8 published signals
Presence & Recognition
Biointron is exhibiting at booth #6 at The Westin Boston Seaport in Boston, Massachusetts, on September 15 to 17, 2026, for a conversation about bsAbs.
Reported by Biointron
Research & Knowledge
Biointron published a recent review describing the required regulatory deliverables and a roadmap for sequencing key workstreams for ADCs.
Reported by Biointron
Products & Services
Biointron launched the RushData Assay Discount Bundle for new customers to save on antibody candidates.
Reported by Biointron
Presence & Recognition
Biointron is attending the ARDD 2026 meeting on October 1-3, 2026 at the David Rubenstein Treehouse in Boston, MA, with Booth #10.
Reported by Biointron
Presence & Recognition
Biointron is hosting a 1-on-1 meeting in Boston on September 15-17, 2026, at The Westin Boston Seaport, featuring a conversation on advances in bispecific antibody development.
Reported by Biointron
Research & Knowledge
Biointron published a study showing structure-guided disulfide engineering restricted Fab movement in human IgG2 to produce meaningful gains in CD40 and 4-1BB agonism.
Reported by GANG LIU
Research & Knowledge
Biointron published a study showing engineered Fab-Fab interactions shifted conventional IgGs toward a compact i-shaped conformation.
Reported by GANG LIU
Legal & Regulatory
Biointron announced that Regeneron received the first approval of Pasatru (garetosmab-grts) by the US FDA for a fully human IgG4 monoclonal antibody targeting Activin A for Fibrodysplasia ossificans progressiva (FOP).
Reported by Biointron